|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the influence of sex on the short-term and long-term effects of subthalamic nucleus stimulation (STN-DBS) in Parkinson's disease (PD) METHODS: We evaluated 48 male and 52 female PD patients enrolled in our prospective DBS registry who received bilateral STN-DBS between 2005 and 2013 and had 5-year follow-up data.
|
31621625 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine patients with Parkinson's disease underwent DBS implantation in the subthalamic nucleus.
|
31216311 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-contrast hybrid images can be used for precisely directed DBS targeting, e.g., GPi DBS for the treatment of advanced Parkinson's disease.
|
31604332 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigate whether the ventroanterior (VA) and ventrolateral (VL) motor nuclei of the thalamus can serve as novel and effective DBS targets for PD.
|
30890329 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Education level is associated with DT-related gait changes in PD one year post-DBS.
|
31621623 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET).
|
30875687 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found different metabolic changes during DBS-STN among patients with PIGD, concerning brain regions that are already known to be involved in gait disorders in Parkinson's disease, suggesting that DBS is responsible for the appearance of PIGD.
|
31350641 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This case report presents a 54-year-old Parkinson´s disease patient who underwent a DBS implantation to the subthalamic nuclei bilaterally.
|
31852004 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the existence of placebo and micro-lesion effects has been convincingly demonstrated in DBS for major depression and Parkinson's disease, systematic investigations for obsessive-compulsive disorder (OCD) are currently lacking.
|
31383848 |
2019 |
|
Tremor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Antero-dorso-medial stimulation site in the STA were associated with less tremor and adverse effects in our small single-center cohort of ET patients with thalamic DBS.
|
30981663 |
2019 |
|
Tremor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET).
|
30875687 |
2019 |
|
Tremor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Indeed, PSA is a promising target for DBS for intractable proximal and distal tremor, even in cases of previous, suboptimal functional neurosurgery.
|
31600751 |
2019 |
|
Tremor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We also propose possible pathophysiological explanations for the phenomenon and define a nomenclature of the associated features: early versus late DBS failure; tremor rebound versus habituation (to be preferred over tolerance).
|
31433906 |
2019 |
|
Essential Tremor
|
0.100 |
Biomarker
|
disease |
BEFREE |
OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET).
|
30875687 |
2019 |
|
Essential Tremor
|
0.100 |
Biomarker
|
disease |
BEFREE |
High frequency Deep brain stimulation (DBS) targeting motor thalamus is an effective therapy for essential tremor (ET).
|
30827864 |
2019 |
|
Essential Tremor
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the motor thalamus is the most popular DBS target for ET, and it is known that the thalamic nucleus plays a key role in relaying information about the external environment to the cerebral cortex, it is important to investigate mechanisms of thalamic DBS in the context of the cerebello-thalamo-cortical neuronal network.
|
31680866 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Pallidal deep-brain stimulation of the internal globus pallidus (GPi-DBS) is an effective treatment for dystonia.
|
30623266 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to assess whether the thalamic ventral intermediate nucleus (Vim) might be an alternative DBS target in dystonia-choreoathetosis.
|
30718219 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, DBS for PD can cause dystonia such as blepharospasm and bilateral pallidal DBS for dystonia can result in features of parkinsonism.
|
31078682 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
DBS has been trialed to treat related movement disorders, particularly dystonia.
|
30633810 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Peak low frequency IMC functioned as biomarker for GPi-DBS efficacy, and partly correlated with dystonia severity.
|
31207566 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A dramatic and long-lasting response to DBS is characteristic of DYT-KMT2B dystonia.
|
31216378 |
2019 |
|
Dystonia Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
To objectively investigate the impact of GPi-DBS on patients with dystonia on speech fluency, intelligibility, and key aspects of hyperkinetic and hypokinetic dysarthria.
|
29576500 |
2019 |
|
Motor symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical trials have established subthalamic deep-brain-stimulation (STN-DBS) as a highly effective treatment for motor symptoms of Parkinson disease (PD), but in clinical practice outcomes are variable.
|
30839077 |
2019 |
|
Motor symptoms
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The whole group (n = 36) was assessed using motor, non-motor symptoms (sleep disturbances in particular) and quality of life measures (QoL), before surgery, 6 and 12 months after DBS programming.
|
30975618 |
2019 |